Vernal Keratoconjunctivitis Market to Surpass US$ 443.0 Million by 2028

Global Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, and Others), by Dosage Form (Gel, Ointment, Tablet, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 346.9 Mn in 2021 and is expected to exhibit a CAGR of 3.6% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Rising advances in technology and research & development activities for a better understanding of the disease is anticipated to spur the global vernal keratoconjuctivities market growth during the forecast period. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments.

In addition, the growing incidence of vernal keratoconjuctivitis and supportive therapies have built the interest of several pharmaceutical companies such as Santen, Novartis Pharmaceuticals, and Allakos in developing a cure for the disease, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.

Global Vernal Keratoconjunctivitis Market- Impact of Coronavirus (COVID-19) Pandemic

Conjunctivitis is a frequent, self-limiting symptom of the COVID-19. In most countries such as United States, Canada, and Japan, urgent and necessary treatments were permitted.

For instance, in March 2020, The American Society of Retina Specialists issued advice to assist retina practices and medical staff in reducing risk and ensuring patient health and safety during the COVID-19 epidemic. The recommendations define the necessary visits for patients and give a method to classify emergent, urgent, and non-urgent visits.

Browse 30 Market Data Tables and 36 Figures spread through 321 Pages and in-depth TOC on “Global Vernal Keratoconjunctivitis Market”- Forecast to 2028, Global Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, and Others), by Dosage Form (Gel, Ointment, Tablet, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Vernal Keratoconjunctivitis Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/vernal-keratoconjunctivitis-market-4657

Emerging new market players and ongoing clinical trials offer useful opportunities for the global vernal keratoconjunctivitis market during the forecast period. A meta-evaluation of randomized managed trials in vernal keratoconjunctivitis discovered extensive variety of research assessing the efficacy of antiallergic eye drops (mipragoside, NAAGA, lodoxamide, nedocromil sodium, levocabastine DCG), with lodoxamide performing to be the maximum successful drug. Santen (Osaka, Japan) has evolved Papilock mini and Verkazia, each of that are mainly suggested for the treatment of VKC.

Key Takeaways of the Global Vernal Keratoconjunctivitis Market:

• Global vernal keratoconjunctivitis market is expected to exhibit a CAGR of 6% during the forecast period owing to increasing prevalence of vernal keratoconjunctivitis as well as the emergence of drugs that used in the treatment of vernal keratoconjunctivitis. First-line pharmacologic treatment encompass topical antihistamines and mast cell stabilizers. Calcineurin inhibitors, and oral antihistamines, nonsteroidal anti-inflammatory medicines (NSAIDs) can be useful in certain people.
• Based on drug type, tacrolimus segment is estimated to account for largest market share in global vernal keratoconjunctivitis market in 2021. Tacrolimus is a nonsteroidal immune suppressant produced from Streptomyces tsukubaensis bacterium. Tacrolimus, 0.1% tacrolimus ointment is effective in controlling the clinical signs and symptoms of severe VKC.
• Among treatment, topical corticosteroids segment is estimated to account for largest market share in vernal keratoconjunctivitis market in 2021. One of the most effective drugs for controlling the signs and symptoms of VKC is topical corticosteroids.
  Topical corticosteroid, cyclosporine relieves symptoms of VKC. In certain cases of VKC, low doses of cyclosporine are used.
• On the basis of dosage form, ointment segment is estimated to account for largest market share in global vernal keratoconjunctivitis market in 2021. Topical antihistamines are first-line drug therapies for vernal keratoconjunctivitis. Patients with vernal keratoconjunctivitis who are unresponsive to two to three weeks of treatment with a double-acting antihistamine / mast cell stabilizer, especially those with significant seasonal exacerbations, may require short-term high-dose pulse therapy with topical corticosteroids.
• On the basis of distribution channel, hospital pharmacy segment is estimated to account for largest market share in global vernal keratoconjunctivitis market in 2021. Increasing visits to hospitals for regular eye checkup and others is major factor boosting the global vernal keratoconjunctivitis market growth.
• Among regions, North America is expected to exhibit highest CAGR in the global vernal keratoconjunctivitis market in 2021. Increasing prevalence of vernal keratoconjunctivitis and growth in the use of modern medications to improve results is anticipated to drive the market growth. For instance, in May 12, 2018, in Gambella town, a community based cross-sectional study was conducted. By using a systematic random sampling technique total 578 study participants were selected. A total of 578 children participated in this study represented a response rate of 99.30%. Vernal conjunctivitis is becoming more common, there are more major players in the region as well as people are becoming more conscious related to ophthalmic diseases are anticipated to drive the market growth.
• Major players operating in the global vernal keratoconjunctivitis market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.